Expectations for Adverum’s WetAMD Phase 1 Data in September
Insights - ADVM will present Phase 1 data in Wet AMD this September We set expectations for September data by looking at competitor RGNX Phase 1 data … Continue Reading
Premium: Read NowInsights
Key Takeaways From Bellus’ Chronic Cough KOL Call
Insights - Bellus hosted their Chronic Cough KOL meeting this morning. It was paneled by: Jacky Smith: lead investigator of Bellus Phase 2 trials Denis Garceau: Bellus VP of … Continue Reading
Read NowMerck’s Plan of a P2X3 Pipeline Lifts Bellus
Insights - Last week, Bellus (BLUSF) rallied from $1.50 range to over $2.00, touching a high of $2.31. This all happened on heavy volume. Remember, we first … Continue Reading
Read NowLate 2019 Data Could Position Gene Therapy Company As Leading Candidate in Wet AMD
Insights - Adverum (ADVM) has rallied year to date from $3.50 to $10/share as the market is picking up on the gene therapy story. With data in … Continue Reading
Premium: Read Now
Acer’s Clinically Relevant Data Could Be Enough For Desperate Patient Population
Insights - Acer Therapeutics (ACER) has a PDUFA date on June 25, 2019 for the treatment of vascular Ehlers-Danlos syndrome (“vEDS”). vEDS is a serious rare disease … Continue Reading
Premium: Read Now
With Completion of Spring Bank’s (SBPH) ACHIEVE, All Eyes on Gilead’s Combination Data
Insights - Spring Bank (SBPH) presented data for their Phase 2 ACHIEVE trial at EASL conference today, including their 200mg cohort. Data was in line with expectations and confirms … Continue Reading
Read Now
Aldeyra’s Allergic Conjunctivitis Data Positions Candidate Well in Dry Eye Disease
Insights - This morning Aldeyra released topline data for their Phase 3 candidate reproxalap in allergic conjunctivitis. The company showed statistical significance in both primary and secondary endpoints Primary … Continue Reading
Read Now